Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration
NCT ID: NCT06024148
Last Updated: 2023-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
250 participants
OBSERVATIONAL
2023-09-30
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The individual and collective stakes are high. Fracture is the most feared complication of osteoporosis. The current under-diagnosis and under-treatment of this chronic pathology exposes patients to a high risk of early re-fracture, with the associated morbidity and mortality.
General practitioners have a major role to play in monitoring and coordinating patients' healthcare pathways. The aim of this study is to assess ways of improving osteoporosis management in order to improve quality of life and disability-free life expectancy for individual patients. The public health and economic stakes are equally high. It is by identifying the obstacles that prospective work on the key elements to be implemented could help optimize osteoporosis management.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
NCT02347865
Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy
NCT04861142
Secondary Prevention of Osteoporosis
NCT00421343
Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication
NCT02472782
Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia
NCT05386784
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sending of an information letter and request for non-objection from patients or their trusted support person, with a 1-month cooling-off period to express opposition.
Collection of variables of interest from CMR patients' medical records, followed by administration of a telephone hetero-questionnaire (transferred to Excel) to patients or their families 1 year after fracture occurrence.
If the patient or family did not answer the questionnaire, or if it was incomplete (missing data), the information could be sought by telephone from the attending physician.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients hospitalized in the Geriatric Rehabilitation Department
patients aged 75 and over, admitted with a severe osteoporotic post-fracture, having received a first dose of antiosteoporotic treatment between the day of fracture and discharge from Geriatric Rehabilitation Department
phone survey
patients complete a 10-minute telephone questionnaire on their osteoporosis management
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
phone survey
patients complete a 10-minute telephone questionnaire on their osteoporosis management
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 75 and over
* Admitted with severe post-fracture osteoporosis
* Having received a first dose of antiosteoporotic treatment between the day the fracture occurred and discharge from CMR (either in an inpatient unit prior to CMR, or at CMR)
Exclusion Criteria
* Subject under guardianship or deprived of liberty.
* Pathological fracture
* Anti-osteoporotic treatment prior to fracture
* 1-year follow-up made impossible by lack of contact with patient, family or attending physician.
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC23.0179
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.